Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Nasopharyngeal Carcinoma 3 Melanoma 3 Esophageal Neoplasms 2 Vascular Complications 1 Stomach Neoplasms 1 Spinocerebellar Degenerations 1 Solid Tumor 1 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Oligoprogressive 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Meningeal Carcinomatosis 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Locally Advanced Rectal Cancer 1 Glioma 1 Esophageal Squamous Cell Carcinoma 1 Diffuse Intrinsic Pontine Glioma 1 Colorectal Cancer Metastatic 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Anus Neoplasms 1

Interventions

pembrolizumab 36 Bevacizumab 25 Cyclophosphamide 22 Blood Specimen Collection 18 Nivolumab 17 Carboplatin 15 Standard of Care 14 Paclitaxel 14 atezolizumab 13 Gemcitabine 13 Exercise 13 Pemetrexed 11 Fluorouracil 11 Doxorubicin 11 Cisplatin 11 Cetuximab 10 Radiotherapy 9 Oxaliplatin 9 Magnetic Resonance Spectroscopy 9 Leucovorin 9 Docetaxel 9 durvalumab 8 abemaciclib 8 Temozolomide 8 Surveys and Questionnaires 8 Rituximab 8 Prednisone 8 Biopsy 8 130-nm albumin-bound paclitaxel 8 olaparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Immune Checkpoint Inhibitors × 90 days × Clear all

NCT07593053 2026-05-22

PIPO

Vall d'Hebron Institute of Oncology

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡